NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
06/16/2026
Back to search
Official data from USPTO
ENTICER
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
06/16/2026
Trademark type
Word
Nice classes
5, 42
Filing date
01/23/2024
Registration date
12/23/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/23/2025
Last transaction
06/16/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
Oxford, Oxfordshire, GB
Examiner
LAWRENCE, SUSAN KASTRINER
Current location
Historical data usage
Holders and representatives
Holders
Enara Bio Limited
Representatives
Amanda M. Prose Westman, Champlin & Koehler P.A.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalspharmaceuticals for the treatment of cancers and tumors in humans; medical preparationsimmunotherapeutic agents for the treatment and prevention of cancers and tumors in humans; Medical preparations in the nature of immunotherapeutic agents for the treatment and prevention of cancers and tumors in humans.
Class 42
Scientific and technological servicesresearch and design in the fields of geneticsimmunotherapyoncology and cancer or tumor therapy; industrial research in the fields of geneticsimmunotherapyoncology and cancer therapy; medical and pharmacological research services; medical research services; research and development of medicines; research and development of immunotherapeutic agents and medicinesof oncology and cancer therapeutic agents and medicines.
Publications
History of USPTO decisions and trademark events.
33 publications found
A7OK
AMENDMENT UNDER SECTION 7 - PROCESSED
05/27/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/18/2026
ES7R
TEAS SECTION 7 REQUEST RECEIVED
02/16/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/23/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
12/23/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/04/2025
PUBO
PUBLISHED FOR OPPOSITION
11/04/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/29/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/24/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/24/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
09/24/2025
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
06/25/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/25/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/25/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/25/2025
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
06/25/2025
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
06/25/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/25/2025
GNFR
FINAL REFUSAL E-MAILED
03/25/2025
CNFR
FINAL REFUSAL WRITTEN
03/25/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/19/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/19/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/19/2025
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
11/04/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
11/04/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/20/2024
GNRT
NON-FINAL ACTION E-MAILED
08/20/2024
CNRT
NON-FINAL ACTION WRITTEN
08/20/2024
DOCK
ASSIGNED TO EXAMINER
08/19/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/23/2024
NWAP
NEW APPLICATION ENTERED
01/23/2024
Continuous trademark protection
Get notified about every new filing that threatens ENTICER or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.